

PHARMACEUTICAL 2022

ALIMERA SCIENCES INC Rank 131 of 466









PHARMACEUTICAL 2022



ALIMERA SCIENCES INC Rank 131 of 466

The relative strengths and weaknesses of ALIMERA SCIENCES INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ALIMERA SCIENCES INC compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 132% points. The greatest weakness of ALIMERA SCIENCES INC is the variable Other Expenses, reducing the Economic Capital Ratio by 91% points.

The company's Economic Capital Ratio, given in the ranking table, is 208%, being 130% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	42,160
Cost of Goods Sold	0
Intangible Assets	10,897
Liabilities, Current	12,592
Liabilities, Non-Current	0
Other Assets	2,680
Other Compr. Net Income	-1,296
Other Expenses	38,529
Other Liabilities	0
Other Net Income	1,680
Other Revenues	59,029
Property and Equipment	2,783
Research and Development	13,778
Selling, General and Administrative Expense	12,774

Output Variable	Value in 1000 USD
Assets	58,520
Liabilities	12,592
Expenses	65,081
Revenues	59,029
Stockholders Equity	45,928
Net Income	-4,372
Comprehensive Net Income	-5,020
Economic Capital Ratio	208%

